| scholarly article | Q13442814 |
| P356 | DOI | 10.4049/JIMMUNOL.164.11.5683 |
| P698 | PubMed publication ID | 10820244 |
| P2093 | author name string | J T Chang | |
| E M Shevach | |||
| B M Segal | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5683-5688 | |
| P577 | publication date | 2000-06-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo | |
| P478 | volume | 164 |
| Q37736589 | 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: immune therapies of type 1 diabetes: new opportunities based on the hygiene hypothesis |
| Q48175463 | Active induction of experimental allergic encephalomyelitis |
| Q35078163 | Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG oligonucleotide |
| Q44625295 | An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems |
| Q36591050 | Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases |
| Q37316205 | BCG and BCG/DNAhsp65 vaccinations promote protective effects without deleterious consequences for experimental autoimmune encephalomyelitis |
| Q27487859 | Broad-Spectrum Drugs Against Viral Agents |
| Q57267014 | Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy |
| Q34079342 | Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. |
| Q58895994 | Characteristics of oligodeoxyribonucleotides that induce interferon (IFN)-α in the pig and the phenotype of the IFN-α producing cells |
| Q82217117 | Circumventing tolerance at the T cell or the antigen-presenting cell surface: antibodies that ligate CD40 and OX40 have different effects |
| Q35025722 | CpG DNA as a vaccine adjuvant. |
| Q38348932 | CpG-Containing Oligodeoxynucleotide 1826 Converts the Weak Uveitogenic Rat Interphotoreceptor Retinoid-Binding Protein Peptide 1181–1191 into a Strong Uveitogen |
| Q74452320 | CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease |
| Q27006858 | Delivery of host cell-directed therapeutics for intracellular pathogen clearance |
| Q52842475 | Development of short non-CpG phosphodiester oligonucleotides as immune stimulatory agents. |
| Q36474285 | Herpes Simplex Virus Type 1 DNA Is Immunostimulatory In Vitro and In Vivo |
| Q47664362 | Humoral immunoreaction induced by TCR DNA vaccine for beta chain of T cell lymphoma |
| Q36742236 | IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. |
| Q40675102 | Immunostimulatory DNA as adjuvant: efficacy of phosphodiester CpG oligonucleotides is enhanced by 3' sequence modifications |
| Q35730784 | Immunotherapeutic uses of CpG oligodeoxynucleotides |
| Q34312767 | Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis |
| Q34680345 | Interferon‐β inhibits toll‐like receptor 9 processing in multiple sclerosis |
| Q42242989 | Long-term in vivo imaging of translated RNAs for gene therapy. |
| Q37526582 | Mycobacterium tuberculosis, autoimmunity, and vitamin D. |
| Q36370956 | Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year |
| Q24682799 | Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo |
| Q36567230 | Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis. |
| Q34117705 | Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta |
| Q35084902 | Protection against experimental autoimmune myocarditis is mediated by interleukin-10-producing T cells that are controlled by dendritic cells |
| Q33356029 | Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses |
| Q36941477 | Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers. |
| Q38345338 | Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides |
| Q53644235 | Roles of Toll-like receptors 2 and 4 in mediating experimental autoimmune orchitis induction in mice. |
| Q34975805 | Streptococcus pneumoniae Infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. |
| Q35105181 | Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs) |
| Q42408498 | TLR-4 ligation of dendritic cells is sufficient to drive pathogenic T cell function in experimental autoimmune encephalomyelitis. |
| Q33938242 | The role of TLR2, TRL3, TRL4, and TRL9 signaling in the pathogenesis of autoimmune disease in a retinal autoimmunity model |
| Q34422017 | The role of dendritic cells in tissue-specific autoimmunity. |
| Q36422953 | Toll-like receptors in central nervous system glial inflammation and homeostasis |
| Q34510368 | Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential |
| Q34721972 | Toll-like receptors in multiple sclerosis |
| Q36293311 | Toxicity of cationic lipid-DNA complexes |
| Q34602052 | Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders |
| Q43735065 | Treatment of experimental autoimmune encephalomyelitis in SJL/J mice with a replicative HSV-1 vector expressing interleukin-5. |
| Q28591514 | Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis |
Search more.